epirubicin has been researched along with Triple Negative Breast Neoplasms in 73 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 45 (61.64) | 24.3611 |
| 2020's | 28 (38.36) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, Y; Cheng, MY; Gao, HF; Ji, F; Li, J; Lin, Y; Liu, Z; Wang, K; Wu, ZY; Yang, CQ; Yang, M; Zhang, G; Zhang, L; Zhu, T | 1 |
| Cheung, P; Chiu, JW; Kwok, G; Kwong, A; Leung, R; Li, B; Suen, D; Tsang, J; Wong, TT; Yau, T | 1 |
| Adachi, T; Eguchi, S; Hayashi, H; Hidaka, M; Itoh, S; Kanetaka, K; Kawaguchi, Y; Kobayashi, K; Kuba, S; Meng, X; Morita, M | 1 |
| Brugman, W; de Boo, LW; Hauptmann, M; Joensuu, H; Jóźwiak, K; Kluin, RJC; Kok, M; Lauttia, S; Lindman, H; Linn, SC; Nederlof, PM; Opdam, M; Schouten, PC; van Steenis, C | 1 |
| Andrews, AG; Chacko, RT; Georgy, JT; Joel, A; John, AO; Premkumar, PS; Sharma, P; Singh, A | 1 |
| Jiang, YZ; Li, D; Pei, Y; Shao, Z; Yang, F; You, C; Zhang, Y | 1 |
| Lukong, KE; Mandapati, A | 1 |
| Aiso, T; Hasegawa, S; Igarashi, Y; Kimura, Y; Nihei, Y; Ohnishi, K; Ohtake, H; Sai, Y; Satou, T; Takasu, N | 1 |
| Asaoka, M; Ishikawa, T; Kawate, T; Miyahara, K; Muguruma, M; Teraoka, S | 1 |
| Fan, L; Liu, Y; Shao, ZM; Wang, ZH | 1 |
| Belleville, E; Brucker, SY; Erber, R; Fasching, PA; Fehm, TN; Häberle, L; Hack, CC; Hartkopf, AD; Hartmann, A; Hein, A; Janni, W; Kolberg, HC; Rübner, M; Theuser, AK; Uhrig, S; Untch, M | 1 |
| Fan, Z; He, Y; Li, J; Ouyang, T; Wang, J; Wang, T; Wang, X | 1 |
| Abraham, DT; Backianathan, S; Balakrishnan, R; Chacko, RT; Cherian, AJ; George, TK; Georgy, JT; Joel, A; John, AO; Manipadam, MT; Patole, S; Paul, MJ; Ramnath, N; Rebekah, G; Sebastian, P; Sharma, P; Sigamani, E; Singh, A; Thumaty, DB | 1 |
| Broeks, A; Cimino-Mathews, A; Daletzakis, A; de Boo, L; Hooijberg, E; Horlings, HM; Kok, M; Linn, S; Loncova, Z; Lubeck, Y; Opdam, M; Rieder, D; Sanders, J; Sobral-Leite, M; Trajanoski, Z; van de Vijver, K; van der Wiel, R; van Rossum, A; van Tinteren, H; Vollebergh, M | 1 |
| Asleh, K; Brauer, HA; Chumsri, S; Joensuu, H; Lauttia, S; Lindman, H; Nielsen, TO; Sullivan, A; Thompson, EA | 1 |
| Fujita, T; Ishikawa, T; Narui, K; Oba, M; Sato, E; Teraoka, S; Yamada, A; Yamada, K | 1 |
| Aktan, G; Bergh, J; Cardoso, F; Cortes, J; Denkert, C; Dent, R; Fasching, PA; Foukakis, T; Harbeck, N; Hui, R; Jia, L; Karantza, V; Kümmel, S; McArthur, H; O'Shaughnessy, J; Park, YH; Pusztai, L; Schmid, P; Takahashi, M; Untch, M; Zhao, J | 1 |
| Cao, Y; Cui, S; Fan, Z; Fu, P; Guo, X; He, P; He, Q; Jiang, G; Jiang, J; Jin, F; Li, J; Li, X; Liu, P; Liu, Y; Ma, B; Mo, M; Pang, D; Qu, X; Rao, N; Ren, G; Shao, Z; Sheng, Y; Sun, Q; Tang, J; Wang, C; Wang, J; Wang, O; Wang, S; Wang, X; Xu, B; Yang, S; Yu, K; Yu, S; Zhang, G; Zhang, H; Zhang, J; Zhuang, Z | 1 |
| Lambertini, M; Perachino, M; Poggio, F | 1 |
| Asaoka, M; Ishikawa, T; Kawate, T; Kuroda, M; Miyagi, Y; Miyahara, K; Muguruma, M; Okazaki, M; Teraoka, S; Ueda, A | 1 |
| Gao, J; Li, X; Liang, X; Liu, Y; Yalamarty, SSK; Zhang, J; Zhang, P; Zheng, Q; Zhou, X; Zou, Q | 1 |
| Alaniz, L; Caon, I; Icardi, A; Parnigoni, A; Passi, A; Sevic, I; Spinelli, FM; Vigetti, D; Vitale, DL | 1 |
| Abraham, DT; Andrews, AG; Backianathan, S; Balakrishnan, R; Chacko, RT; Chandramohan, J; Cherian, AJ; Georgy, JT; Joel, A; John, AO; Manipadam, MT; Paul, MJ; Rebekah, G; Sigamani, E; Singh, A; Thumaty, DB | 1 |
| Bongiovanni, A; De Vita, A; Evangelopoulos, M; Hartman, KA; Ibrahim, T; Liverani, C; Martinez, JO; Mercatali, L; Miserocchi, G; Molinaro, R; Pieri, F; Spadazzi, C; Taraballi, F; Tasciotti, E | 1 |
| Chen, JJ; Cioccoloni, G; Henn, MA; Hughes, TA; Hutchinson, SA; Kim, B; Lianto, P; Ma, L; Moore, JB; Nelson, E; Pramanik, A; Rose, A; Røberg-Larsen, H; Soteriou, C; Thorne, JL; Wastall, LM; Websdale, A; Williams, BJ | 1 |
| Adriaenssens, E; Angrand, PO; Bidan, N; Chopin, V; Lagadec, C; Le Bourhis, X; Meignan, S; Toillon, RA; Völkel, P; Winter, M | 1 |
| Ding, X; Gao, N; Gong, QH; Jia, GF; Jiang, XX; Lei, L; Li, J; Li, ZQ; Shen, LW; Wang, M | 1 |
| Denkert, C; Forstbauer, H; Hoffmann, G; Karn, T; Kohls, A; Köhne, CH; Linn, SC; Loibl, S; Marmé, F; Möbus, VJ; Nekljudova, V; Schem, C; Schmatloch, S; Schouten, PC; Solbach, C; Thomssen, C; van Rossum, AGJ; von Minckwitz, G; Weber, KE | 1 |
| Li, S; Liang, Y; Ren, L; Tang, P; Wang, S; Wu, X; Zhang, T; Zhang, Y; Zhong, L | 1 |
| Liu, S; Qin, Y; Song, X; Sun, Z; Wang, Y; Yang, J; Yu, K; Zhang, S; Zhou, X | 1 |
| Gwak, H; Jeon, YW; Kang, EY; Kim, SY; Lee, HJ; Lim, ST; Moon, BI; Nam, SJ; Park, CH; Suh, YJ | 1 |
| Blohmer, JU; Costa, SD; Couch, FJ; Fasching, PA; Fehm, T; Gerber, B; Hart, SN; Hilfrich, J; Hu, C; Huober, J; Ingle, JN; Liedtke, C; Loibl, S; Moore, R; Müller, V; Nekljudova, V; Rack, B; Rezai, M; Rübner, M; Schem, C; Shimelis, H; Tesch, H; Untch, M; von Minckwitz, G; Wang, L; Weber, KE; Weinshilboum, RM | 1 |
| He, X; Li, F; Lu, Y; Sun, C; Xu, X; Zhang, L; Zhang, P | 1 |
| Clemons, M; Fergusson, D; Hilton, J; Hutton, B; Mazzarello, S; Stober, C; Vandermeer, L | 1 |
| Chen, S; Ji, R; Li, C; Tang, P; Wang, Q; Wen, J | 1 |
| Gong, Y; Hao, S; Jiang, YZ; Jin, X; Ren, YX; Shao, ZM; Ye, FG | 1 |
| Ashley, D; Baron-Hay, S; Chisanga, D; Collins, I; Khasraw, M; Liao, Y; Lindeman, G; Mukaro, V; Murphy, C; Muscat, A; Patil, S; Shi, W; West, L | 1 |
| Blohmer, JU; Burchardi, N; Denkert, C; Engels, K; Fasching, PA; Furlanetto, J; Grischke, EM; Hanusch, C; Huober, J; Jackisch, C; Kümmel, S; Loibl, S; Rautenberg, B; Rezai, M; Rhiem, K; Schmitt, WD; Schneeweiss, A; Sinn, BV; Tesch, H; Thomalla, J; Untch, M; von Minckwitz, G; Weber, K | 1 |
| Arioka, H; Chishima, T; Doi, T; Endo, I; Ichikawa, Y; Ishikawa, T; Kida, K; Kosaka, Y; Kuranami, M; Mogaki, M; Morita, S; Narui, K; Nawata, S; Niikura, N; Oba, MS; Ogata, H; Ota, T; Saito, Y; Sasaki, T; Sengoku, N; Shimizu, D; Suto, A; Suzuki, Y; Tanabe, M; Tokuda, Y; Tsugawa, K; Yamada, A | 1 |
| Futsuhara, K; Hata, S; Inoue, K; Kimizuka, K; Kojima, M; Kuroda, T; Nagai, SE; Saito, T; Sakurai, T; Yamada, H; Yamazaki, Y | 1 |
| Cai, RG; Li, Q; Wang, JY; Wang, X; Xu, BH; Xu, XZ; Yin, Y; Yuan, P; Zhang, BL; Zhang, P | 1 |
| Aitini, E; Bighin, C; Bisagni, G; Clavarezza, M; De Placido, S; Del Mastro, L; Durando, A; Galli, A; Garrone, O; Levaggi, A; Restuccia, E; Saracchini, S; Scalamogna, R; Turazza, M | 1 |
| Aittomäki, K; Blomqvist, C; Carpén, O; Fagerholm, R; Heikkilä, P; Heikkinen, T; Khan, S; Korpela, T; Nevanlinna, H | 1 |
| Blohmer, JU; Eggemann, H; Eidtmann, H; Fasching, PA; Gerber, B; Hanusch, C; Hauschild, M; Huober, J; Jackisch, C; Kittel, K; Kreienberg, R; Kunz, G; Loibl, S; Nekljudova, V; Rezai, M; Schrader, I; Solbach, C; Tesch, H; Untch, M; von Minckwitz, G | 1 |
| Amadori, D; Biglia, N; Brandi, M; Bravaccini, S; Cerasoli, S; Faedi, M; Gianni, L; Giunchi, DC; Maltoni, R; Mangia, A; Medri, L; Paradiso, A; Petroni, S; Puccetti, M; Ricci, M; Rocca, A; Scarpi, E; Serra, L; Silvestrini, R; Sismondi, P; Tienghi, A | 1 |
| Barranger, E; Bertheau, P; Bousquet, G; de Bazelaire, C; Ferreira, I; Feugeas, JP; Janin, A; Jourdan, N; Vercellino, L | 1 |
| Albiter, M; Bertheau, P; Bouhidel, F; Cottu, PH; Coussy, F; Cuvier, C; de Roquancourt, A; de Thé, H; Espié, M; Extra, JM; Giacchetti, S; Hamy, AS; Lehmann-Che, J; Marty, M; Porcher, R | 1 |
| Balci, S; Cascione, L; Croce, CM; Fassan, M; Gasparini, P; Guler, G; Huebner, K; Irkkan, C; Lovat, F; Morrison, C; Shapiro, CL | 1 |
| Akcakanat, A; Brewster, AM; Chen, H; Crawford, D; Do, KA; Dryden, MJ; Flores, P; Giordano, SH; Gonzalez-Angulo, AM; Green, MC; Hortobagyi, GN; Ibrahim, NK; Koenig, KB; Litton, JK; Liu, S; Meric-Bernstam, F; Mills, GB; Moore, J; Moulder-Thompson, S; Murray, JL; Palla, SL; Pusztai, L; Sahin, A; Symmans, WF; Tarco, E; Valero, V | 1 |
| Abeysundara, N; Bally, MB; Bortnik, S; Chittaranjan, S; DeVorkin, L; Dragowska, WH; Gelmon, K; Go, NE; Gorski, SM; Leung, A; Weppler, SA; Xu, J; Yapp, DT | 1 |
| Ah Lee, S; Gwe Ahn, S; Jeong, J; Min Lee, H; Woo Lee, H | 1 |
| Berger, F; de Cremoux, P; de Roquancourt, A; Espié, M; Giacchetti, S; Groheux, D; Hamy, AS; Hatt, M; Hindié, E; Marty, M; Merlet, P | 1 |
| Higaki, K; Kuroi, K; Masuda, N; Matsunami, N; Miyamoto, T; Mizutani, M; Morimoto, T; Morita, S; Ohno, S; Ohtani, S; Takano, T; Toi, M | 1 |
| de Vries, EG; Hauptmann, M; Jonkers, J; Linn, SC; Lips, EH; Nederlof, PM; Rodenhuis, S; van Tinteren, H; Vd Vijver, MJ; Vollebergh, MA; Wesseling, J; Wessels, LF | 1 |
| Anan, K; Hayashi, M; Kamata, Y; Maeda, S; Mashino, K; Matsuo, S; Mitsuyama, S; Nishimura, J; Tamura, K; Tanaka, M; Toyoshima, S; Yamaguchi, Y; Yamamoto, Y; Yoshinaga, Y | 1 |
| Ashmawy, AM; Bahhnassy, A; El-Bastawisy, A; Ismail, MF; Mohanad, M; Shaarawy, S; Zekri, AR | 1 |
| Chen, S; Di, GH; Jiang, YZ; Jin, X; Shao, ZM; Yu, KD | 1 |
| Bagnardi, V; Barberis, M; Cancello, G; Colleoni, M; Dellapasqua, S; Goldhirsch, A; Intra, M; Iorfida, M; Luini, A; Montagna, E; Sangalli, C; Sporchia, A; Veronesi, P; Viale, G | 1 |
| Alvarez, R; Briones, B; Ibrahim, N; Karakas, C; Keyomarsi, K; Mitri, Z; Moulder, S; Murray, JL; Simmons, H; Wei, C | 1 |
| Andre, F; Conte, P; Delaloge, S; Dieci, MV; Goubar, A; Guarneri, V; Mathieu, MC | 1 |
| Fox, MJ; Gibbs, P; Pickles, MD | 1 |
| Asano, Y; Hirakawa, K; Kashiwagi, S; Kawajiri, H; Kitagawa, S; Noda, S; Ohsawa, M; Onoda, N; Takashima, T | 1 |
| A L-Abdulkarim, H; A L-Tweigeri, T; Abulkhair, O; Ajarim, D; Alawadi, S; AlSayed, A; Ashour, W; Ibrahim, M; Jaafar, H; Khalid, H | 1 |
| Akazawa, K; Hasegawa, Y; Hayashi, M; Horiguchi, J; Ishikawa, T; Kim, SJ; Kohno, N; Konishi, M; Kubota, T; Miura, D; Miyashita, M; Shigeoka, Y; Suzuki, M; Taguchi, T; Takao, S; Tanino, H; Yamagami, K | 1 |
| Biard, L; Cuvier, C; de Cremoux, P; de Roquancourt, A; Espié, M; Giacchetti, S; Groheux, D; Hindié, E; Merlet, P; Resche-Rigon, M; Teixeira, L; Vercellino, L | 1 |
| Chen, X; Dong, JF; Li, M; Liu, W; Wang, CY; Wang, M; Xie, XF; Yang, AJ; Zhang, LH | 1 |
| Endo, I; Ichikawa, Y; Ishikawa, T; Kida, K; Narui, K; Oba, MS; Tanabe, M; Yamada, A | 1 |
| Hu, YH; Li, XR; Liu, L; Zhang, J | 1 |
| He, W; Jin, HY; Liu, Q; Liu, YF; Wang, XF; Wei, ZX | 1 |
| Cai, R; Fan, Y; Li, Q; Ma, F; Mo, H; Wang, J; Wang, X; Xu, B; Yin, Y; Yuan, P; Zhang, B; Zhang, P; Zheng, S | 1 |
| Hou, H; Li, T; Liu, C; Liu, D; Liu, K; Lv, H; Wang, G; Zhang, C; Zhang, X; Zhou, N; Zhu, J | 1 |
| Collignon, J; Delvenne, P; Donneau, AF; Feyereisen, E; Foidart, P; Gofflot, S; Jerusalem, G; Lienard, M; Noël, A; Schroeder, H; Somja, J; Sounni, NE; Truong, A; Yip, C | 1 |
| Ahlgren, J; Auvinen, P; Bono, P; Huovinen, R; Joensuu, H; Jukkola-Vuorinen, A; Junnila, J; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Kosonen, S; Lahdenperä, O; Lindman, H; Nilsson, G; Nyandoto, P; Poikonen-Saksela, P; Tanner, M; Villman, K | 1 |
1 review(s) available for epirubicin and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
[A Case of Stage Ⅳ Triple Negative Breast Cancer(TNBC)in Which S-1 Was Successful against Armor-Like Infiltration of the Chest Wall].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Female; Humans; Middle Aged; Paclitaxel; Thoracic Wall; Triple Negative Breast Neoplasms | 2022 |
31 trial(s) available for epirubicin and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Triple Negative Breast Neoplasms | 2022 |
Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Homologous Recombination; Humans; Triple Negative Breast Neoplasms | 2022 |
Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2023 |
Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer - A single-arm phase II trial (NeoImmunoboost, AGO-B-041).
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Platinum; Prospective Studies; Quality of Life; Treatment Outcome; Triple Negative Breast Neoplasms | 2023 |
Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Protein; Carboplatin; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphocytes, Tumor-Infiltrating; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Thiotepa; Triple Negative Breast Neoplasms | 2020 |
Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Prognosis; Survival Rate; Triple Negative Breast Neoplasms | 2020 |
Neoadjuvant Chemotherapy With Anthracycline-Based Regimen for BRCAness Tumors in Triple-Negative Breast Cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Pilot Projects; Prospective Studies; Treatment Outcome; Triple Negative Breast Neoplasms | 2020 |
Pembrolizumab for Early Triple-Negative Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Triple Negative Breast Neoplasms | 2020 |
Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Prospective Studies; Time Factors; Triple Negative Breast Neoplasms | 2020 |
BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Capecitabine; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Humans; Middle Aged; Myeloablative Agonists; Neoplasm Recurrence, Local; Paclitaxel; Triple Negative Breast Neoplasms | 2017 |
A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Axilla; Cyclobutanes; Docetaxel; Epirubicin; Female; Follow-Up Studies; Humans; Mammary Glands, Human; Middle Aged; Neoadjuvant Therapy; Odds Ratio; Organoplatinum Compounds; Remission Induction; Taxoids; Thrombocytopenia; Treatment Outcome; Triple Negative Breast Neoplasms | 2018 |
BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; BRCA1 Protein; BRCA2 Protein; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Genotype; Germ-Line Mutation; Humans; Neoadjuvant Therapy; Receptor, ErbB-2; Triple Negative Breast Neoplasms | 2018 |
Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Docetaxel; Doxorubicin; Endpoint Determination; Epirubicin; Feasibility Studies; Female; Fluorouracil; Guideline Adherence; Humans; Middle Aged; Paclitaxel; Pilot Projects; Random Allocation; Surveys and Questionnaires; Triple Negative Breast Neoplasms | 2018 |
Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of response.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Nanoparticles; Neoadjuvant Therapy; Paclitaxel; Receptor, ErbB-2; Serum Albumin, Human; Trastuzumab; Triple Negative Breast Neoplasms | 2019 |
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Breast; Cyclophosphamide; Double-Blind Method; Epirubicin; Female; Humans; Hyperthyroidism; Hypothyroidism; Lymphocytes, Tumor-Infiltrating; Mastectomy; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Placebos; Prospective Studies; Receptor, ErbB-2; Thyroid Gland; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2019 |
Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Japan; Kaplan-Meier Estimate; Mastectomy, Segmental; Middle Aged; Prognosis; Prospective Studies; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms | 2019 |
Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Paclitaxel; Taxoids; Treatment Failure; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Humans; Inflammatory Breast Neoplasms; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Everolimus; Female; Humans; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Sirolimus; Treatment Outcome; Triple Negative Breast Neoplasms; Tumor Burden; Ultrasonography; Young Adult | 2013 |
Benefit from anthracyclines in relation to biological profiles in early breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Immunohistochemistry; Ki-67 Antigen; Methotrexate; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triple Negative Breast Neoplasms | 2014 |
Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Epirubicin; Everolimus; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms | 2014 |
A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triple Negative Breast Neoplasms; Young Adult | 2014 |
Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2015 |
A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cyclic N-Oxides; Cyclin-Dependent Kinases; Epirubicin; Female; Humans; Indolizines; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Pyridinium Compounds; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Lymphocytes, Tumor-Infiltrating; Middle Aged; Multivariate Analysis; Prognosis; Receptor, ErbB-2; Tamoxifen; Triple Negative Breast Neoplasms | 2015 |
Predictive Value of Neutrophil/Lymphocyte Ratio for Efficacy of Preoperative Chemotherapy in Triple-Negative Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphocytes; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutrophils; Paclitaxel; Preoperative Care; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate; Triple Negative Breast Neoplasms | 2016 |
A multicenter prospective phase II trial of neoadjuvant epirubicin, cyclophosphamide, and 5-fluorouracil (FEC100) followed by cisplatin-docetaxel with or without trastuzumab in locally advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diphosphonates; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Genes, erbB-2; Humans; Imidazoles; Middle Aged; Neoadjuvant Therapy; Treatment Outcome; Triple Negative Breast Neoplasms; Zoledronic Acid | 2015 |
BRCAness is beneficial for indicating triple negative breast cancer patients resistant to taxane.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Bridged-Ring Compounds; Cyclophosphamide; Drug Administration Schedule; Drug Resistance, Neoplasm; Epirubicin; Female; Fluorouracil; Humans; Immunohistochemistry; Middle Aged; Multiplex Polymerase Chain Reaction; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Recurrence; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Finland; Fluorouracil; Humans; Middle Aged; Receptors, Estrogen; Receptors, Progesterone; Sweden; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2017 |
41 other study(ies) available for epirubicin and Triple Negative Breast Neoplasms
| Article | Year |
|---|---|
Neoadjuvant Therapy with Concurrent Docetaxel, Epirubicin, and Cyclophosphamide (TEC) in High-Risk HER2-Negative Breast Cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Neoadjuvant Therapy; Receptor, ErbB-2; Treatment Outcome; Triple Negative Breast Neoplasms | 2021 |
Bilateral Inflammatory Breast Cancer That Developed Two Years after Treatment for Triple-negative Breast Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; Humans; Inflammatory Breast Neoplasms; Lymph Node Excision; Mastectomy; Sentinel Lymph Node Biopsy; Triple Negative Breast Neoplasms | 2022 |
Anemia requiring transfusion in breast cancer patients on dose-dense chemotherapy: Prevalence, risk factors, cost and effect on disease outcome.
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Prevalence; Risk Factors; Thrombocytopenia; Treatment Outcome; Triple Negative Breast Neoplasms | 2022 |
Integration of radiogenomic features for early prediction of pathological complete response in patients with triple-negative breast cancer and identification of potential therapeutic targets.
Topics: Breast Neoplasms; Epirubicin; Female; Humans; Magnetic Resonance Imaging; Neoadjuvant Therapy; Retrospective Studies; Triple Negative Breast Neoplasms | 2022 |
Triple negative breast cancer: approved treatment options and their mechanisms of action.
Topics: Docetaxel; Doxorubicin; Epirubicin; Humans; Paclitaxel; Triple Negative Breast Neoplasms; United States | 2023 |
β-Tubulin Isoforms Related to Docetaxel Sensitivity in 2D and 3D Cultured TNBC Cell Lines.
Topics: Cell Line; Cell Line, Tumor; Cisplatin; Docetaxel; Epirubicin; Humans; Protein Isoforms; Triple Negative Breast Neoplasms; Tubulin | 2022 |
Observation Effectiveness of Dose-Dense Neoadjuvant Anthracycline Sequential Weekly Paclitaxel for Triple-Negative Breast Cancer Patients.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2023 |
Dose-Dense Docetaxel-Cyclophosphamide and Epirubicin-Cisplatin(ddDCEP): Analysis of an Alternative Platinum-Containing Regimen in 116 Patients with Early Triple Negative Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Neoadjuvant Therapy; Platinum; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2023 |
Call for assessing treatment-induced gonadotoxicity of platinum-based chemotherapy in early breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Ovary; Paclitaxel; Primary Ovarian Insufficiency; Randomized Controlled Trials as Topic; Treatment Outcome; Triple Negative Breast Neoplasms | 2020 |
Differences in drug sensitivity between two-dimensional and three-dimensional culture systems in triple-negative breast cancer cell lines.
Topics: Antineoplastic Agents; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Inhibitory Concentration 50; Spheroids, Cellular; Triple Negative Breast Neoplasms | 2020 |
Self-Assembled Dual-Targeted Epirubicin-Hybrid Polydopamine Nanoparticles for Combined Chemo-Photothermal Therapy of Triple-Negative Breast Cancer.
Topics: Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Cell Survival; Epirubicin; Female; Humans; Hyperthermia, Induced; Indoles; Lasers; Mice, Inbred BALB C; NAD; Nanoparticles; Neoplasms, Experimental; Particle Size; Phototherapy; Polymers; Rats, Sprague-Dawley; Reactive Oxygen Species; Temperature; Tissue Distribution; Triple Negative Breast Neoplasms | 2020 |
Initial Identification of UDP-Glucose Dehydrogenase as a Prognostic Marker in Breast Cancer Patients, Which Facilitates Epirubicin Resistance and Regulates Hyaluronan Synthesis in MDA-MB-231 Cells.
Topics: Antibiotics, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Epirubicin; Female; Humans; Hyaluronic Acid; Prognosis; Triple Negative Breast Neoplasms; Uridine Diphosphate Glucose Dehydrogenase | 2021 |
Pathological response and clinical outcomes in operable triple-negative breast cancer with cisplatin added to standard neoadjuvant chemotherapy.
Topics: Adult; Anemia; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Retrospective Studies; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2021 |
Lysyl oxidase engineered lipid nanovesicles for the treatment of triple negative breast cancer.
Topics: Animals; Antibiotics, Antineoplastic; Antibodies; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Delivery Systems; Drug Therapy, Combination; Epirubicin; Extracellular Matrix; Female; Humans; Liposomes; Mice; Mice, Nude; Nanoparticles; Protein-Lysine 6-Oxidase; Tissue Distribution; Treatment Outcome; Triple Negative Breast Neoplasms; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |
Liver x receptor alpha drives chemoresistance in response to side-chain hydroxycholesterols in triple negative breast cancer.
Topics: Animals; Benzoates; Benzylamines; Cell Line, Tumor; Drug Resistance, Neoplasm; Epirubicin; Female; Gene Expression; Humans; Hydroxycholesterols; Liver X Receptors; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Triple Negative Breast Neoplasms | 2021 |
Vimentin Promotes the Aggressiveness of Triple Negative Breast Cancer Cells Surviving Chemotherapeutic Treatment.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cyclophosphamide; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Therapy; Epirubicin; Epithelial-Mesenchymal Transition; Female; Humans; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Paclitaxel; Triple Negative Breast Neoplasms; Vimentin; Zebrafish | 2021 |
Cepharanthine sensitizes human triple negative breast cancer cells to chemotherapeutic agent epirubicin via inducing cofilin oxidation-mediated mitochondrial fission and apoptosis.
Topics: Actin Depolymerizing Factors; Antineoplastic Agents; Apoptosis; Benzylisoquinolines; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Epirubicin; Humans; Mitochondrial Dynamics; Molecular Structure; Oxidation-Reduction; Structure-Activity Relationship; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2022 |
Emodin inhibits epithelial‑mesenchymal transition and metastasis of triple negative breast cancer via antagonism of CC‑chemokine ligand 5 secreted from adipocytes.
Topics: Adipocytes; Adult; Animals; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemokine CCL5; Coculture Techniques; Emodin; Epirubicin; Epithelial-Mesenchymal Transition; Female; Humans; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Signal Transduction; Triple Negative Breast Neoplasms | 2018 |
The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Humans; Methotrexate; Middle Aged; Prognosis; Registries; Republic of Korea; Retrospective Studies; Survival Analysis; Triple Negative Breast Neoplasms | 2018 |
TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis.
Topics: Antibiotics, Antineoplastic; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Epirubicin; Epithelial-Mesenchymal Transition; Female; Humans; Neoplastic Stem Cells; Transforming Growth Factor beta; Triple Negative Breast Neoplasms | 2018 |
A Minimal lncRNA-mRNA Signature Predicts Sensitivity to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cyclophosphamide; Databases, Genetic; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Remission Induction; RNA, Long Noncoding; RNA, Messenger; ROC Curve; Transcriptome; Triple Negative Breast Neoplasms | 2018 |
Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Mastectomy; Mastectomy, Segmental; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Retrospective Studies; Taxoids; Triple Negative Breast Neoplasms | 2019 |
TS-1 add-on therapy in Japanese patients with triple-negative breast cancer after neoadjuvant or adjuvant chemotherapy: a feasibility study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Epirubicin; Feasibility Studies; Female; Follow-Up Studies; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Silicates; Survival Rate; Titanium; Triple Negative Breast Neoplasms | 2020 |
Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cyclophosphamide; Cytarabine; Doxorubicin; Epirubicin; Eukaryotic Initiation Factor-4E; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Proteins; Paraffin Embedding; Phenotype; Prognosis; Protein Biosynthesis; Tissue Array Analysis; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Individual xenograft as a personalized therapeutic resort for women with metastatic triple-negative breast carcinoma.
Topics: Adult; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Mammary Neoplasms, Animal; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Paclitaxel; Taxoids; Transplantation, Heterologous; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Middle Aged; Neoadjuvant Therapy; Prognosis; Prospective Studies; Survival Rate; Survivors; Triple Negative Breast Neoplasms; Young Adult | 2014 |
microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Docetaxel; Down-Regulation; Doxorubicin; Epirubicin; ErbB Receptors; Female; Fluorouracil; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Keratin-5; Keratin-6; Methotrexate; MicroRNAs; Middle Aged; Oligonucleotide Array Sequence Analysis; Paclitaxel; Prognosis; Risk Assessment; Survival Rate; Taxoids; Triple Negative Breast Neoplasms; Up-Regulation | 2014 |
Autophagy inhibition augments the anticancer effects of epirubicin treatment in anthracycline-sensitive and -resistant triple-negative breast cancer.
Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Apoptosis; Autophagy; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Mice; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
In vitro chemoresponse assay based on the intrinsic subtypes in breast cancer.
Topics: Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; In Vitro Techniques; Ki-67 Antigen; Mastectomy; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2014 |
Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Taxoids; Tomography, X-Ray Computed; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Protein; Carboplatin; Comparative Genomic Hybridization; Cyclophosphamide; DNA Breaks, Double-Stranded; DNA Repair; Epirubicin; Female; Fluorouracil; Homologous Recombination; Humans; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Thiotepa; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
[Effect of weekly paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide as neoadjuvant treatment for patients with triple-negative and luminal-type breast cancer - a multicenter study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2015 |
Transforming growth factor-β, insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor I; Middle Aged; Neoplasm Metastasis; Prognosis; Receptor, IGF Type 1; Transforming Growth Factor beta1; Treatment Outcome; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A | 2015 |
Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Epirubicin; Estrogens; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Progesterone; Prognosis; Proportional Hazards Models; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2015 |
Minkowski functionals: An MRI texture analysis tool for determination of the aggressiveness of breast cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biopsy; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Therapy; Epirubicin; Female; Humans; Image Processing, Computer-Assisted; Lymphatic Metastasis; Magnetic Resonance Imaging; Middle Aged; Prognosis; Reproducibility of Results; Retrospective Studies; Software; Statistics, Nonparametric; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Recurrence, Local; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
Enhanced autophagy reveals vulnerability of P-gp mediated epirubicin resistance in triple negative breast cancer cells.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Autophagy; Beclin-1; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; NF-kappa B; RNA Interference; RNA, Small Interfering; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2016 |
[Relevance between TOP2A, EGFR gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer patients].
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; DNA Topoisomerases, Type II; DNA-Binding Proteins; Docetaxel; Epirubicin; Female; Gene Expression; Genes, erbB-1; Humans; Neoadjuvant Therapy; Poly-ADP-Ribose Binding Proteins; Receptor, ErbB-2; Retrospective Studies; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
Efficacy of intra-arterial neoadjuvant chemotherapy through the superior epigastric artery in the treatment of locally advanced triple negative breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Epigastric Arteries; Epirubicin; Female; Humans; Neoadjuvant Therapy; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma.
Topics: Albumin-Bound Paclitaxel; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Breast; Carcinoma; Chemotherapy, Adjuvant; Circulating Tumor DNA; Cisplatin; Cyclophosphamide; Disease Progression; Drug Resistance, Neoplasm; Epirubicin; ErbB Receptors; Female; Hand-Foot Syndrome; High-Throughput Nucleotide Sequencing; Humans; Hypertension; Lung Neoplasms; Mastectomy, Modified Radical; Middle Aged; Mutation; Neovascularization, Pathologic; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sequence Analysis, DNA; Thoracic Neoplasms; Treatment Failure; Triple Negative Breast Neoplasms | 2016 |
MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Epirubicin; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Matrix Metalloproteinases, Membrane-Associated; Mice; Mice, Nude; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |